Reuters logo
10 个月前
BRIEF-Biomarin Pharmaceutical provided update on mod-stage study of vosoritide
2016年10月19日 / 晚上9点37分 / 10 个月前

BRIEF-Biomarin Pharmaceutical provided update on mod-stage study of vosoritide

Oct 19 (Reuters) - Biomarin Pharmaceutical Inc

* Biomarin Pharmaceutical - Provided update on phase 2 study of vosoritide, analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia

* Vosoritide was generally well tolerated at all doses

* Biomarin Pharmaceutical Inc - Biomarin is planning a separate phase 2 study evaluating effect of vosoritide in infants and toddlers

* Biomarin Pharmaceutical-By 2016-end, intends to initiate 1-year,randomized, placebo-controlled phase 3 study in children with achondroplasia ages 5-14 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below